Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Capital Expenditures (2017 - 2021)

Cogent Biosciences has reported Capital Expenditures over the past 4 years, most recently at $433000.0 for Q4 2021.

  • Quarterly results put Capital Expenditures at $433000.0 for Q4 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was $1.6 million (changed N/A YoY), and the annual figure for FY2025 was $1.6 million, up 171.2%.
  • Capital Expenditures for Q4 2021 was $433000.0 at Cogent Biosciences, down from $1.2 million in the prior quarter.
  • Over the last five years, Capital Expenditures for COGT hit a ceiling of $1.2 million in Q3 2021 and a floor of -$737000.0 in Q4 2017.
  • Median Capital Expenditures over the past 4 years was $80500.0 (2018), compared with a mean of $187750.0.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 255.2% in 2018 and later plummeted 125.58% in 2019.
  • Cogent Biosciences' Capital Expenditures stood at -$737000.0 in 2017, then skyrocketed by 111.67% to $86000.0 in 2018, then plummeted by 84.88% to $13000.0 in 2019, then surged by 3230.77% to $433000.0 in 2021.
  • The last three reported values for Capital Expenditures were $433000.0 (Q4 2021), $1.2 million (Q3 2021), and $13000.0 (Q4 2019) per Business Quant data.